First-pass metabolism of midazolam by the human intestine

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 14-24

  Paine, Mary F ^a   Shen, Danny D ^a   Kunze, Kent L ^a   Perkins, James D ^a   Marsh, Christopher L ^a   McVicar, John P ^a   Barr, Darlene M ^a   Gillies, Bruce S ^a   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450; MIDAZOLAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DUODENUM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

EID: 0029738490     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90162-9     Document Type: Article

References (35)

1. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
2. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993;21:403-9.
3. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
4. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20: 753-61.
5. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985;40:457-76.
6. Ptachcinski RJ, Venkataramanan R, Burckart G. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986;11:107-32.
7. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
8. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
9. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59.
10. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporine by the gut. Lancet 1991;338:1488-90.
11. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
12. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
13. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-43.
14. Fabre G, Rahmani R, Placidi M, et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 1988;37:4389-97.
15. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
16. 14C-midazolam in humans following oral dosing. Arzneimittel forschung 1981;31:2220-3.
17. Kanto JH. Midazolam: the first water-soluble benzodiazepine: pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. Pharmacotherapy 1985;5:138-55.
18. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe, 1: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
19. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994;22:947-55.
20. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther [in press].
21. Park GR, Manara AR, Dawling S. Extra-hepatic metabolism of midazolam. Br J Clin Pharmacol 1989;27: 634-7.
22. Shaw BW, Martin DJ, Marquez JM, et al. Venous bypass in clinical transplantation. Ann Surg 1984;200: 524-33.
23. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cyctochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
24. 2-valproic acid to rat plasma proteins. Pharm Res 1990;7:461-7.
25. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.
26. Fahr A. Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-95.
27. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658-61.
28. Mahon WA, Inaba T, Stone RM. Metabolism of flurazepam by the small intestine. Clin Pharmacol Ther 1977;22:228-33.
29. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990;253:287-94.
30. Klippert P, Borm P, Noordhoek J. Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data: correlation with in vivo data using mucosal blood flow. Biochem Pharmacol 1982; 31:2545-8.
31. Ilett KF, Tee LBG, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990;46:67-93.
32. Gwilt PR, Comer S, Chaturvedi PR, Waters DH. The influence of diffusional barriers on presystemic gut elimination. Drug Metab Dispos 1988;16:521-6.
33. Schuetz EG, Schuetz JD, McLean Grogan W, et al. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992;294: 206-14.
34. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism: intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995;82:689-99.
35. Haehner BD, Gorski JC, VandenBranden M, et al. Bimodal distribution of renal cytochrome P4503A activity in humans. Mol Pharmacol [in press].